Protease-Activated Receptors

Platelets

Volumn , Issue , 2013, Pages 249-259

  Zhang, Ping ^a   Covic, Lidija ^a   Kuliopulos, Athan ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882574711     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-387837-3.00013-4     Document Type: Chapter

References (98)

1. Ruggeri Z.M. Platelets in atherothrombosis. Nat Med 2002, 8(11):1227-1234.
2. Leger A.J., Covic L., Kuliopulos A. Protease-activated receptors and cardiovascular diseases. Circulation 2006, 113:1070-1077.
3. Vu T.K., Hung D.T., Wheaton V.I., Coughlin S.R. Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell 1991, 64(6):1057-1068.
4. Rasmussen U.B., Vouret-Craviari V., Jallat S., Schlesinger Y., Pages G., Pavirani A., et al. cDNA cloning and expression of a hamster alpha-thrombin receptor coupled to Ca2+ mobilization. FEBS Lett 1991, 288(1-2):123-128.
5. Nystedt S., Emilsson K., Wahlestedt C., Sundelin J. Molecular cloning of a potential proteinase activated receptor. Proc Natl Acad Sci USA 1994, 91:9208-9212.
6. Ishihara H., Connolly A.J., Zeng D., Kahn M.L., Zheng Y.W., Timmons C., et al. Protease-activated receptor 3 is a second thrombin receptor in humans. Nature 1997, 386:502-506.
7. Kahn M.L., Zheng Y.-W., Huang W., Bigornia V., Zheng D., Moff S., et al. A dual thrombin receptor system for platelet activation. Nature 1998, 394:690-694.
8. Xu W.-F., Andersen H., Whitmore T.E., Presnell S.R., Yee D.P., Ching A., et al. Cloning and characterization of human protease-activated receptor 4. Proc Natl Acad Sci USA 1998, 95:6642-6646.
9. Leger A., Jacques S.L., Badar J., Kaneider N.C., Derian C.K., Andrade-Gordon P., et al. Blocking the protease-activated receptor 1-4 heterodimer in platelet-mediated thrombosis. Circulation 2006, 113:1244-1254.
10. Frungieri M.B., Weidinger S., Meineke V., Kohn F.M., Mayerhofer A. Proliferative action of mast-cell tryptase is mediated by PAR2, COX2, prostaglandins, and PPARgamma: possible relevance to human fibrotic disorders. Proc Natl Acad Sci USA 2002, 99(23):15072-15077.
11. Seitz I., Hess S., Schulz H., Eckl R., Busch G., Montens H.P., et al. Membrane-type serine protease-1/matriptase induces interleukin-6 and -8 in endothelial cells by activation of protease-activated receptor-2: potential implications in atherosclerosis. Arterioscler Thromb Vasc Biol 2007, 27(4):769-775.
12. Oldham W.M., Van Eps N., Preininger A.M., Hubbell W.L., Hamm H.E. Mapping allosteric connections from the receptor to the nucleotide-binding pocket of heterotrimeric G proteins. Proc Natl Acad Sci USA 2007, 104(19):7927-7932.
13. Oldham W.M., Hamm H.E. How do receptors activate G proteins?. Adv Protein Chem 2007, 74:67-93.
14. Paing M.M., Stutts A.B., Kohout T.A., Lefkowitz R.J., Trejo J. β-Arrestins regulate protease-activated receptor-1 desensitization but not internalization or down-regulation. J Biol Chem 2002, 277(2):1292-1300.
15. Trejo J., Connolly A.J., Coughlin S.R. The cloned thrombin receptor is necessary and sufficient for activation of mitogen-activated protein kinase and mitogenesis in mouse lung fibroblasts. Loss of responses in fibroblasts from receptor knockout mice. J Biol Chem 1996, 271(35):21536-21541.
16. Vu T.-K.H., Wheaton V.I., Hung D.T., Charo I., Coughlin S.R. Domains specifying thrombin-receptor interaction. Nature 1991, 353:674-677.
17. Jacques S., LeMasurier M., Sheridan P.J., Seeley S.K., Kuliopulos A. Substrate-assisted catalysis of the PAR1 thrombin receptor: enhancement of macromolecular association and cleavage. J Biol Chem 2000, 275(52):40671-40678.
18. Jacques S.L., Kuliopulos A. Protease-activated receptor-4 uses dual prolines and an anionic recognition motif for thrombin recognition and cleavage. Biochem J. 2003, 376:733-740.
19. Seeley S., Covic L., Jacques S.L., Sudmeier J., Baleja J.D., Kuliopulos A. Structural basis for thrombin activation of a protease-activated receptor: inhibition of intramolecular liganding. Chemistry & Biology 2003, 10:1033-1041.
20. Bahou W.F., Coller B.S., Potter C.L., Norton K.J., Kutok J.L., Goligorsky M.S. The thrombin receptor extracellular domain contains sites crucial for peptide ligand-induced activation. J Clin Invest 1993, 91:1405-1413.
21. Gerszten R.E., Chen J., Ishii M., Ishii K., Wang L., Nanevicz T., et al. Specificity of the thrombin receptor for agonist peptide is defined by its extracellular surface. Nature 1994, 368(6472):648-651.
22. Nanevicz T., Ishii M., Wang L., Chen M., Chen J., Turck C.W., et al. Mechanisms of thrombin receptor agonist specificity. Chimeric receptors and complementary mutations identify an agonist recognition site. J Biol Chem 1995, 270(37):21619-21625.
23. Blackhart B.D., Ruslim-Litrus L., Lu C.-C., Alves V.L., Teng W., Scarborough R.M., et al. Extracellular mutations of protease-activated receptor-1 result in differential activation by thrombin and thrombin receptor agonist peptide. Mol Pharmacol 2000, 58:1178-1187.
24. Gandhi P.S., Chen Z., Appelbaum E., Zapata F., Di Cera E. Structural basis of thrombin-protease-activated receptor interactions. IUBMB Life 2011, 63(6):375-382.
25. Rydel T.J., Ravichandran K.G., Tulinski A., Bode W., Huber R., Roitsch C., et al. The structure of a complex of recombinant hirudin and human α-thrombin. Science 1990, 249:277-280.
26. Kuliopulos A., Covic L., Seeley S.K., Sheridan P.J., Helin J., Costello C.E. Plasmin desensitization of the PAR1 thrombin receptor: Kinetics, sites of truncation, and implications for thrombolytic therapy. Biochemistry 1999, 38:4572-4585.
27. Riewald M., Petrovan R.J., Donner A., Mueller B.M., Ruf W. Activation of endothelial cell protease activated receptor 1 by the protein C pathway. Science 2002, 296:1880-1882.
28. Parry M.A.A., Myles T., Tschopp J., Stone S.R. Cleavage of the thrombin receptor: identification of potential activators and inactivators. Biochem J. 1996, 320:335-341.
29. Koukos G., Sevigny L., Zhang P., Covic L., Kuliopulos A. Serine and metalloprotease signaling through PAR1 in arterial thrombosis and vascular injury. IUBMB Life 2011, 63:412-418.
30. Trivedi V., Boire A., Tchernychev B., Kaneider N.C., Leger A.J., O'Callaghan K., et al. Platelet matrix metalloprotease-1 mediates thrombogenesis by activating PAR1 at a cryptic ligand site. Cell 2009, 137:332-343.
31. Huang J.S., Dong L., Kozasa T., Le Breton G.C. Signaling through G(alpha)13 switch region I is essential for protease-activated receptor 1-mediated human platelet shape change, aggregation, and secretion. J Biol Chem 2007, 282(14):10210-10222.
32. 2 and thrombin receptors in human platelets. Proc Natl Acad Sci USA 1994, 91:504-508.
33. Boire A., Covic L., Agarwal A., Jacques S., Sharifi S., Kuliopulos A. PAR1 is a matrix metalloprotease-1 receptor that promotes invasion and tumorigenesis of breast cancer cells. Cell 2005, 120:303-313.
34. Tressel S.L., Kaneider N.C., Kasuda S., Foley C., Koukos G., Austin K., et al. A matrix metalloprotease-PAR1 system regulates vascular integrity, systemic inflammation and death in sepsis. EMBO Mol Med 2011, 3:370-384.
35. Goerge T., Barg A., Schnaeker E.-M., Poppelmann B., Shpacovitch V., Rattenholl A., et al. Tumor-derived matrix metalloprotease-1 targets endothelial proteinase-activated receptor 1 promoting endothelial cell activation. Cancer Res 2006, 66:7766-7774.
36. Blackburn J.S., Brinckerhoff C.E. Matrix metalloproteinase-1 and thrombin differentially activate gene expression in endothelial cells via PAR-1 and promote angiogenesis. Am J Pathol 2008, 173(6):1736-1746.
37. Agarwal A., Covic L., Sevigny L.M., Kaneider N.C., Lazarides K., Azabdaftari G., et al. Targeting a metalloprotease-PAR1 signaling system with cell-penetrating pepducins inhibits angiogenesis, ascites, and progression of ovarian cancer. Mol Cancer Ther 2008, 7(9):2746-2757.
38. Yang E., Boire A., Agarwal A., Nguyen N., O'Callaghan K., Tu P., et al. Blockade of PAR1 signaling with cell-penetrating pepducins inhibits Akt survival pathways in breast cancer cells and suppresses tumor survival and metastasis. Cancer Res 2009, 69(15):6223-6231.
39. Agarwal A., Tressel S.L., Kaimal R., Balla M., Lam F.H., Covic L., et al. Identification of a metalloprotease--chemokine signaling system in the ovarian cancer microenvironment: implications for anti-angiogenic therapy. Cancer Res 2010, 70:5880-5890.
40. Blackburn J.S., Liu I., Coon C.I., Brinckerhoff C.E. A matrix metalloproteinase-1/protease activated receptor-1 signaling axis promotes melanoma invasion and metastasis. Oncogene 2009, 28(48):4237-4248.
41. Nesi A., Fragai M. Substrate specificities of matrix metalloproteinase 1 in PAR-1 exodomain proteolysis. Chembiochem 2007, 8(12):1367-1369.
42. Gether U., Kolbilka B.K. G protein-coupled receptors II. Mechanism of agonist activation. J Biol Chem 1998, 273:17979-17982.
43. q Subunits. Biochemistry 1997, 36:1487-1495.
44. Cotecchia S., Ostrowski J., Kjelsberg M.A., Caron M.G., Lefkowitz R.J. Discrete amino acid sequences of the alpha 1-adrenergic receptor determine the selectivity of coupling to phosphatidylinositol hydrolysis. J Biol Chem. 1992, 267(3):1633-1639.
45. Kjelsberg M.A., Cotecchia S., Ostrowski J., Caron M.G., Lefkowitz R.J. Constitutive activation of the alpha 1B-adrenergic receptor by all amino acid substitutions at a single site. Evidence for a region which constrains receptor activation. J Biol Chem 1992, 267(3):1430-1433.
46. Gilman A.G. G proteins: transducers of receptor-generated signals. Annu Rev Biochem 1987, 56:615-649.
47. Higashijima T., Uzu S., Nakajima T., Ross E.M. Mastoparan, a peptide toxin from wasp venom, mimics receptors by activating GTP-binding regulatory proteins (G proteins). J Biol Chem 1988, 263(14):6491-6494.
48. Covic L., Gresser A.L., Talavera J., Swift S., Kuliopulos A. Activation and inhibition of G protein-coupled receptors by cell-penetrating membrane-tethered peptides. Proc Natl Acad Sci USA 2002, 99:643-648.
49. Covic L., Misra M., Badar J., Singh C., Kuliopulos A. Pepducin-based intervention of thrombin-receptor signaling and systemic platelet activation. Nat Med 2002, 8(10):1161-1165.
50. Kaneider N.C., Leger A.J., Agarwal A., Nguyen N., Perides G., Derian C., et al. "Role reversal" for the receptor PAR1 in sepsis-induced vascular damage. Nat Immunol 2007, 8(12):1303-1312.
51. Sevigny L.M., Austin K.M., Zhang P., Kasuda S., Koukos G., Sharifi S., et al. Protease-activated receptor-2 modulates protease-activated receptor-1-driven neointimal hyperplasia. Vasc Biol 2011, 31:e100-6.
52. Palczewski K., Kumasaka T., Hori T., Behnke C.A., Motoshima H., Fox B.A., et al. Crystal structure of rhodopsin: a G protein-coupled receptor. Science 2000, 289(5480):739-745.
53. Swift S., Leger A., Talavera J., Zhang L., Bohm A., Kuliopulos A. The role of the PAR1 receptor 8th helix in signaling: the 7-8-1 receptor activation mechanism. J Biol Chem 2006, 278:4109-4116.
54. Dowal L., Sim D.S., Dilks J.R., Blair P., Beaudry S., Denker B.M., et al. Identification of an antithrombotic allosteric modulator that acts through helix 8 of PAR1. Proc Natl Acad Sci USA 2011, 108(7):2951-2956.
55. Swift S., Xu J., Trivedi V., Austin K.M., Tressel S.L., Zhang L., et al. A novel protease-activated receptor-1 interactor, Bicaudal D1, regulates G protein signaling and internalization. J Biol Chem 2010, 285(15):11402-11410.
56. Soh UJ, Dores MR, Chen B, Trejo J. Signal transduction by protease-activated receptors. Br J Pharmacol 2010;160(2):191-203.
57. Ishihara H., Connolly A.J., Zeng D., Kahn M.L., Zheng Y.W., Timmons C., et al. Protease-activated receptor 3 is a second thrombin receptor in humans. Nature 1997, 386(6624):502-506.
58. Nakanishi-Matsui M., Zheng Y.W., Sulciner D.J., Weiss E.J., Ludeman M.J., Coughlin S.R. PAR3 is a cofactor for PAR4 activation by thrombin. Nature 2000, 404(6778):609-613.
59. Sambrano G.R., Huang W., Faruqi T., Mahrus S., Craik C., Coughlin S.R., et al. Activates protease-activated receptor-4 in human platelets. J Biol Chem 2000, 275:6819-6823.
60. Covic L., Gresser A.L., Kuliopulos A. Biphasic kinetics of activation and signaling for PAR1 and PAR4 thrombin receptors in platelets. Biochemistry 2000, 39:5458-5467.
61. Shapiro M.J., Weiss E.J., Faruqi T.R., Coughlin S.R. Protease-activated receptors 1 and 4 are shut off with distinct kinetics after activation by thrombin. J Biol Chem 2000, 275:25216-25221.
62. Celikel R., McClintock R.A., Roberts J.R., Mendolicchio G.L., Ware J., Varughese K.I., et al. Modulation of alpha-thrombin function by distinct interactions with platelet glycoprotein Ibalpha. Science 2003, 301(5630):218-221.
63. Dumas J.J., Kumar R., Seehra J., Somers W.S., Mosyak L. Crystal structure of the GpIbalpha-thrombin complex essential for platelet aggregation. Science 2003, 301(5630):222-226.
64. Cristofaro R.D., Candia E.D., Landolfi R., Rutella S., Hall S.W. Structural and functional mapping of the thrombin domain involved in the binding to the platelet glycoprotein Ib. Biochemistry 2001, 40:13268-13273.
65. Candia E.D., Hall S.W., Rutella S., Landolfi R., Andrews R.K., Cristofaro R.D. Binding of thrombin to glycoprotein Ib accelerates the hydrolysis of PAR1 on intact platelets. J Biol Chem 2001, 276:4692-4698.
66. Ramachandran R., Hollenberg M.D. Proteinases and signalling: pathophysiological and therapeutic implications via PARs and more. Br J Pharmacol 2008, 153(Suppl. 1):S263-S282.
67. Faruqi T.R., Weiss E.J., Shapiro M.J., Huang W., Coughlin S.R. Structure-function analysis of protease-activated receptor 4 tethered ligand peptides. Determinants of specificity and utility in assays of receptor function. J Biol Chem 2000, 275:19728-19734.
68. Becker R.C., Moliterno D.J., Jennings L.K., Pieper K.S., Pei J., Niederman A., et al. Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study. Lancet 2009, 373(9667):919-928.
69. Goto S., Ogawa H., Takeuchi M., Flather M.D., Bhatt D.L. Double-blind, placebo-controlled Phase II studies of the protease-activated receptor 1 antagonist E5555 (atopaxar) in Japanese patients with acute coronary syndrome or high-risk coronary artery disease. Eur Heart J. 2010, 31(21):2601-2613.
70. Macaulay T.E., Allen C., Ziada K.M. Thrombin receptor antagonism: the potential of antiplatelet medication SCH 530348. Expert Opin Pharmacother 2010, 11(6):1015-1022.
71. Morrow D.A., Scirica B.M., Fox K.A., Berman G., Strony J., Veltri E., et al. TRA 2(o)P-TIMI 50 investigators. Am Heart J 2009, 158(3):335-341.
72. MERCK press release. Available from: <>; 2011 [accessed 24.012011]. http://www.fiercebiotech.com/press-releases/merck-statement-changes-clin ical-studies-vorapaxar-0.
73. Tricoci P., Huang Z., Held C., Moliterno D.J., Armstrong P.W., Van de Werf F., et al. Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. N Engl J Med 2012, 366(1):20-33.
74. Coughlin S.R. Protease-activated receptors in hemostasis, thrombosis and vascular biology. J Thromb Haemost 2005, 3(8):1800-1814.
75. Russo A., Soh U.J., Trejo J. Proteases display biased agonism at protease-activated receptors: location matters!. Mol Interv 2009, 9(2):87-96.
76. 13 results in shape change and Rho/Rho-kinase-mediated myosin light chain phosphorylation in mouse platelets. J Cell Biol 1999, 144:745-754.
77. Hers I., Donath J., van Willigen G., Akkerman J.W. Differential involvement of tyrosine and serine/threonine kinases in platelet integrin alphaIIbbeta3 exposure. Arterioscler Thromb Vasc Biol 1998, 18(3):404-414.
78. Walker T.R., Watson S.P. Synergy between Ca2+ and protein kinase C is the major factor in determining the level of secretion from human platelets. Biochem J. 1993, 289(Pt 1):277-282.
79. Trumel C., Payrastre B., Plantavid M., Hechler B., Viala C., Presek P., et al. A key role of adenosine diphosphate in the irreversible platelet aggregation induced by the PAR1-activating peptide through the late activation of phosphoinositide 3-kinase. Blood 1999, 94:4156-4165.
80. Covic L., Singh C., Smith H., Kuliopulos A. Role of the PAR4 thrombin receptor in stabilizing platelet-platelet aggregates as revealed by a patient with Hermansky-Pudlak syndrome. Thromb Haemost 2002, 87:722-727.
81. Hirsch E., Bosco O., Tropel P., Laffargue M., Calvez R., Altruda F., et al. Resistance to thromboembolism in PI3Kgamma-deficient mice. FASEB J 2001, 15(11):2019-2021.
82. Wu C.C., Wu S.Y., Liao C.Y., Teng C.M., Wu Y.C., Kuo S.C. The roles and mechanisms of PAR4 and P2Y12/phosphatidylinositol 3-kinase pathway in maintaining thrombin-induced platelet aggregation. Br J Pharmacol 2010, 161(3):643-658.
83. Cifuni S.M., Wagner D.D., Bergmeier W. CalDAG-GEFI and protein kinase C represent alternative pathways leading to activation of integrin alphaIIbbeta3 in platelets. Blood 2008, 112(5):1696-1703.
84. Bergmeier W., Stefanini L. Novel molecules in calcium signaling in platelets. J Thromb Haemost 2009, 7(Suppl. 1):187-190.
85. Varga-Szabo D., Braun A., Nieswandt B. Calcium signaling in platelets. J Thromb Haemost 2009, 7(7):1057-1066.
86. Parekh A.B., Putney J.W. Store-operated calcium channels. Physiol Rev 2005, 85(2):757-810.
87. Kim S., Foster C., Lecchi A., Quinton T.M., Prosser D.M., Jin J., et al. Protease-activated receptors 1 and 4 do not stimulate G(i) signaling pathways in the absence of secreted ADP and cause human platelet aggregation independently of G(i) signaling. Blood 2002, 99(10):3629-3636.
88. Heemskerk J.W., Vis P., Feijge M.A., Hoyland J., Mason W.T., Sage S.O. Roles of phospholipase C and Ca(2+)-ATPase in calcium responses of single, fibrinogen-bound platelets. J Biol Chem 1993, 268(1):356-363.
89. Hermansky F., Pudlak P. Albinism associated with hemorrhagic diathesis and unusual pigmented reticular cells in the bone marrow: report of two cases with histochemical studies. Blood 1959, 14(2):162-169.
90. Anikster Y., Huizing M., White J., Shevchenko Y.O., Fitzpatrick D.L., Touchman J.W., et al. Mutation of a new gene causes a unique form of Hermansky-Pudlak syndrome in a genetic isolate of central Puerto Rico. Nat Genet 2001, 28(4):376-380.
91. Dale G.L. Coated-platelets: an emerging component of the procoagulant response. J Thromb Haemost 2005, 3(10):2185-2192.
92. Kimmelstiel C., Zhang P., Kapur N.K., Weintraub A., Krishnamurthy B., Castaneda V., et al. Bivalirudin is a dual inhibitor of thrombin and collagen-dependent platelet activation in patients undergoing percutaneous coronary intervention. Circ Cardiovasc Interv 2011, 4(2):171-179.
93. Keuren J.F., Wielders S.J., Ulrichts H., Hackeng T., Heemskerk J.W., Deckmyn H., et al. Synergistic effect of thrombin on collagen-induced platelet procoagulant activity is mediated through protease-activated receptor-1. Arterioscler Thromb Vasc Biol 2005, 25:1499-1505.
94. Dorsam R.T., Tuluc M., Kunapuli S.P. Role of protease-activated and ADP receptor subtypes in thrombin generation on human platelets. J Thromb Haemost 2004, 2(5):804-812.
95. Andersen H., Greenberg D.L., Fujikawa K., Xu W., Chung D.W., Davie E.W. Protease-activated receptor 1 is the primary mediator of thrombin-stimulated platelet procoagulant activity. Proc Natl Acad Sci USA 1999, 96(20):11189-11193.
96. Derian C.K., Damiano B.P., Addo M.F., Darrow A.L., D'Andrea M.R., Nedelman M., et al. Blockade of the thrombin receptor protease-activated receptor-1 with a small-molecule antagonist prevents thrombus formation and vascular occlusion in nonhuman primates. J Pharmacol Exp Ther 2003, 304(2):855-861.
97. Nadal-Wollbold F., Bocquet A., Bourbon T., Letienne R., Le Grand B. Protease-activated receptor 1 antagonists prevent platelet aggregation and adhesion without affecting thrombin time. Eur J Pharmacol 2010, 644(1-3):188-194.
98. Bhatt D.L., Topol E.J. Scientific and therapeutic advances in antiplatelet therapy. Nature Rev Drug Discovery 2003, 2:15-28.